With now over 25 synthetic injectable fillers available in the U.S., one would think there is little need for further filler products. But the ability to modify hyaluronic acid filler structures to create different aesthetic effects assures that more such filler products will continue to become available.
Juvederm Vollure XC has just become FDA-approved for injection into moderate to deep facial wrinkles such as the nasolabial folds. It is formulated with proprietary Vycross technology, which blends different molecular weights of hyaluronic acid, contributing to the filler’s long duration. Juvederm Vollure XC will be available in the United States in April 2017. This specific filler is not new in other parts of the world as it was first approved in Europe under the name of Juvederm Volift in 2013.
In the clinical trial that led to its approval, 59% of patients saw improvement in moderate to severe nasolabial folds for up to 18 months, with 82% of patients saying they were very satisfied at 6 months and 68% at 18 months. With a duration that has been shown to last up to 18 months from the initial or touch-up injection in a majority of patients, this is the longest lasting result shown in a clinical study in the nasolabial folds to date.
Like all injectable fillers it has typical side effects such as swelling, tenderness, bruising, firmness lumps/bumps, redness, pain, discoloration, and itching. Other than lumps of the material these side effects resolved within one week after injection.
Dr. Barry Eppley